Barclays PLC Pyxis Oncology, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Barclays PLC holds 77,013 shares of PYXS stock, worth $103,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77,013
Previous 64,089
20.17%
Holding current value
$103,197
Previous $235,000
48.51%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PYXS
# of Institutions
100Shares Held
24.3MCall Options Held
993KPut Options Held
42.6K-
Laurion Capital Management LP New York, NY3.63MShares$4.86 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$3.99 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$3.27 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.45 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $47M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...